View Financial HealthEndonovo Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Endonovo Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Nov 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/15/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Oct 13Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA ApprovalEndonovo Therapeutics, Inc. announced the full regulatory approval of its product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW). The approval is a significant accomplishment in introducing innovative Pulsed Electro Magnetic Field (PEMF) technology into the Taiwanese surgical market through Endonovo's valued distribution partner, EverMed Medical Enterprises Co. The SofPulse® TFDA approval marks the initial phase of Endonovo's expansion, through EverMed, into the largely untapped PEMF and surgical sectors in Taiwan. Initial sales efforts will focus on introducing SofPulse® into multiple Taiwanese hospital surgical markets. EverMed will target four surgical specialties -- including cardiovascular surgery, orthopedic surgery, spinal surgery and plastic surgery -- representing hundreds of thousands of surgical cases. SofPulse® Commercialization in Taiwan: EverMed and Endonovo’s commercialization of SofPulse® in Taiwan commences with product registration with the NHI. This will be followed by an extensive sales and marketing campaign to introduce surgeons and patients to the benefits of PEMF therapy. Sales and marketing strategies include leveraging existing connections with MD’s, surgeons, hospitals and medical facilities to promote the expansion of surgical applications across Taiwan's three regions. As healthcare professionals and patients experience the tangible benefits of PEMF technology in post-operative care, SofPulse® is poised for success and wide acceptance throughout the Taiwanese surgical market. Taiwan FDA Process and International Expansion: The TFDA is the regulatory arm of Taiwan’s MOHW and is considered the driving force behind healthcare improvement in Taiwan. MOHW's focus is on promoting the health and well-being of all citizens in Taiwan by improving healthcare quality, advancing technological development, ensuring quality, efficiency, resource allocation contributing to international affairs. SofPulse® TFDA approval helps to validate Endonovo’s innovative approach to pain relief and non-opioid alternatives that has garnered widespread attention in the ever-growing global medical markets.공고 • Aug 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/16/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Dec 01Endonovo Therapeutics, Inc. Appoints Ira Weisberg President to Guide Global Medical ExpansionEndonovo Therapeutics, Inc. appointed Ira Weisberg as President and Chief Commercial Officer of its Medical Division. Weisberg has more than four decades of experience in healthcare and pharmaceutical management, business development, finance, sales and marketing. Weisberg’s past work experience includes positions as President and CEO of Amherst Pharmaceuticals, Senior VP and Corporate Development Officer at Neurotrope Bioscience. Other executive medical administrative experience include executive positions at ALPHAVAX, INC., LIFECYCLE PHARMA, CHUGAI PHARMA USA, HAEMACURE CORPORATION and AVENTIS BEHRING.공고 • Nov 15Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/14/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Sep 29Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star.Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star Concrete, LLC from for $25.2 million on September 26, 2022. The deal is conditioned on Employment Agreements signed by Endonovo Therapeutics, The transaction is subject to Due diligence, and audit of Western Star’s financial statements for the years ended December 31, 2021 and December 31. The closing is anticipated to be held on or about December 15, 2022. Jack B. Eggleston of Eggleston King Davis, LLP acted as legal advisor to Endonovo Therapeutics.공고 • Aug 16Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Jul 29Endonovo Therapeutics Releases Comparative Analysis DemonstratingEndonovo Therapeutics, Inc. released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and five published studies for SofPulse®. Product and technical characteristics comparisons for both devices were included in FDA-clearance material for both company’s Pulsed Electric Magnetic Frequency (PEMF) products, which are designed to alleviate post-operative reduction of pain and edema (swelling). Comparison of SofPulse® to RecoveryRx® in technical characteristics demonstrated superiority of the design, efficacy and health benefits of the Endonovo SofPulse® medical device.공고 • May 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/16/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Apr 16Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' DoubtEndonovo Therapeutics, Inc. filed its 10-K on Apr 14, 2022 for the period ending Dec 31, 2021. In this report its auditor, Rose, Snyder & Jacobs, gave an unqualified opinion expressing doubt that the company can continue as a going concern.공고 • Apr 01Endonovo Therapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Mar 03Endonovo Therapeutics Inc. Appoints Garry Michael Kann as Head of Corporate DevelopmentEndonovo Therapeutics Inc. announced that it has appointed Garry Michael Kann as Head of Corporate Development to design, lead and execute its new corporate “build up strategy” of identifying and acquiring complementary specialty service providers in the construction industry. Mr. Kann will be responsible for management and oversight of creation and ongoing operation of all corporate development activities including oversight of potential acquisitions (Targets) identification activities, discussions regarding structuring of Transactions for Endonovo and management and oversite of Endonovo Merger and Acquisition staff. By Endonovo, establishing a Mergers and Acquisition division run by Mr. Kann, Endonovo will become a diversified holding company.공고 • Aug 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/16/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 18Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Apr 02Endonovo Therapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Nov 18Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/16/2020, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Oct 10Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID PandemicEndonovo Therapeutics, Inc. announced a new marketing and public awareness campaign around their FDA Cleared SofPulse® that has been proven to help the in the response to the opioid epidemic during the COVID pandemic. SofPulse® device is FDA Cleared for reduction of pain and edema post-operatively. It offers a non-opioid, non-invasive, non-pharmaceutical opioid mitigation treatment and it has no known side effects based upon over 20,000+ surgical uses since its introduction to post-surgical pain management. Management believes that SofPulse® is a viable solution to manage pain and edema for all in-patient hospital surgeries. However, the true value of adopting this preventative approach to the opioid epidemic is in the lives saved.공고 • Aug 12Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/11/2020, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ENDV 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ENDV 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Endonovo Therapeutics 배당 수익률 vs 시장ENDV의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ENDV)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.1%업계 평균 (Biotechs)2.1%분석가 예측 (ENDV) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ENDV 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ENDV 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ENDV 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ENDV 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/17 10:36종가2026/07/17 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Endonovo Therapeutics, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Nov 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/15/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Oct 13Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA ApprovalEndonovo Therapeutics, Inc. announced the full regulatory approval of its product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW). The approval is a significant accomplishment in introducing innovative Pulsed Electro Magnetic Field (PEMF) technology into the Taiwanese surgical market through Endonovo's valued distribution partner, EverMed Medical Enterprises Co. The SofPulse® TFDA approval marks the initial phase of Endonovo's expansion, through EverMed, into the largely untapped PEMF and surgical sectors in Taiwan. Initial sales efforts will focus on introducing SofPulse® into multiple Taiwanese hospital surgical markets. EverMed will target four surgical specialties -- including cardiovascular surgery, orthopedic surgery, spinal surgery and plastic surgery -- representing hundreds of thousands of surgical cases. SofPulse® Commercialization in Taiwan: EverMed and Endonovo’s commercialization of SofPulse® in Taiwan commences with product registration with the NHI. This will be followed by an extensive sales and marketing campaign to introduce surgeons and patients to the benefits of PEMF therapy. Sales and marketing strategies include leveraging existing connections with MD’s, surgeons, hospitals and medical facilities to promote the expansion of surgical applications across Taiwan's three regions. As healthcare professionals and patients experience the tangible benefits of PEMF technology in post-operative care, SofPulse® is poised for success and wide acceptance throughout the Taiwanese surgical market. Taiwan FDA Process and International Expansion: The TFDA is the regulatory arm of Taiwan’s MOHW and is considered the driving force behind healthcare improvement in Taiwan. MOHW's focus is on promoting the health and well-being of all citizens in Taiwan by improving healthcare quality, advancing technological development, ensuring quality, efficiency, resource allocation contributing to international affairs. SofPulse® TFDA approval helps to validate Endonovo’s innovative approach to pain relief and non-opioid alternatives that has garnered widespread attention in the ever-growing global medical markets.
공고 • Aug 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/16/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Dec 01Endonovo Therapeutics, Inc. Appoints Ira Weisberg President to Guide Global Medical ExpansionEndonovo Therapeutics, Inc. appointed Ira Weisberg as President and Chief Commercial Officer of its Medical Division. Weisberg has more than four decades of experience in healthcare and pharmaceutical management, business development, finance, sales and marketing. Weisberg’s past work experience includes positions as President and CEO of Amherst Pharmaceuticals, Senior VP and Corporate Development Officer at Neurotrope Bioscience. Other executive medical administrative experience include executive positions at ALPHAVAX, INC., LIFECYCLE PHARMA, CHUGAI PHARMA USA, HAEMACURE CORPORATION and AVENTIS BEHRING.
공고 • Nov 15Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/14/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Sep 29Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star.Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star Concrete, LLC from for $25.2 million on September 26, 2022. The deal is conditioned on Employment Agreements signed by Endonovo Therapeutics, The transaction is subject to Due diligence, and audit of Western Star’s financial statements for the years ended December 31, 2021 and December 31. The closing is anticipated to be held on or about December 15, 2022. Jack B. Eggleston of Eggleston King Davis, LLP acted as legal advisor to Endonovo Therapeutics.
공고 • Aug 16Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Jul 29Endonovo Therapeutics Releases Comparative Analysis DemonstratingEndonovo Therapeutics, Inc. released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and five published studies for SofPulse®. Product and technical characteristics comparisons for both devices were included in FDA-clearance material for both company’s Pulsed Electric Magnetic Frequency (PEMF) products, which are designed to alleviate post-operative reduction of pain and edema (swelling). Comparison of SofPulse® to RecoveryRx® in technical characteristics demonstrated superiority of the design, efficacy and health benefits of the Endonovo SofPulse® medical device.
공고 • May 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/16/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Apr 16Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' DoubtEndonovo Therapeutics, Inc. filed its 10-K on Apr 14, 2022 for the period ending Dec 31, 2021. In this report its auditor, Rose, Snyder & Jacobs, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
공고 • Apr 01Endonovo Therapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Mar 03Endonovo Therapeutics Inc. Appoints Garry Michael Kann as Head of Corporate DevelopmentEndonovo Therapeutics Inc. announced that it has appointed Garry Michael Kann as Head of Corporate Development to design, lead and execute its new corporate “build up strategy” of identifying and acquiring complementary specialty service providers in the construction industry. Mr. Kann will be responsible for management and oversight of creation and ongoing operation of all corporate development activities including oversight of potential acquisitions (Targets) identification activities, discussions regarding structuring of Transactions for Endonovo and management and oversite of Endonovo Merger and Acquisition staff. By Endonovo, establishing a Mergers and Acquisition division run by Mr. Kann, Endonovo will become a diversified holding company.
공고 • Aug 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/16/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 18Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Apr 02Endonovo Therapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Nov 18Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/16/2020, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Oct 10Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID PandemicEndonovo Therapeutics, Inc. announced a new marketing and public awareness campaign around their FDA Cleared SofPulse® that has been proven to help the in the response to the opioid epidemic during the COVID pandemic. SofPulse® device is FDA Cleared for reduction of pain and edema post-operatively. It offers a non-opioid, non-invasive, non-pharmaceutical opioid mitigation treatment and it has no known side effects based upon over 20,000+ surgical uses since its introduction to post-surgical pain management. Management believes that SofPulse® is a viable solution to manage pain and edema for all in-patient hospital surgeries. However, the true value of adopting this preventative approach to the opioid epidemic is in the lives saved.
공고 • Aug 12Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/11/2020, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.